Saturday 17 October 2026
Export BOLT’s income statement to Excel — free account
Bolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.06
0.18
−4.25%
Follow BOLT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 1 | 4 | 5 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z-Score |
(12.67) | (7.64) | (3.54) | (1.79) | 0.42 | — | — | — | — |
P/S ratio |
1.33 | 2.66 | 5.57 | 8.93 | 109.10 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
(27.30) | (15.19) | (4.62) | 0.62 | 3.92 | (12.70) | (1.83) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
(1.43) | (1.42) | (3.07) | (2.85) | (9.14) | (5.31) | (5.31) | — | — |
P/B ratio |
0.39 | 0.36 | 0.39 | 0.30 | 0.65 | 0.00 | 0.00 | — | — |
Price to Tangible BV |
0.39 | 0.36 | 0.39 | 0.30 | 0.65 | 0.00 | 0.00 | — | — |
EV/Sales |
0.35 | (0.61) | (5.19) | (17.02) | (1.14) | 0.00 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.06 | 0.52 | 1.10 | 0.02 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(0.07) | 0.08 | 0.59 | 1.27 | 0.03 | (1.16) | (1.16) | — | — |
EV/FCF |
(0.07) | 0.08 | 0.59 | 1.24 | 0.03 | (1.09) | (1.09) | — | — |
Quick Ratio |
3.28 | 3.03 | 5.00 | 7.31 | 8.73 | 2.03 | 4.02 | 4.95 | — |
Current Ratio |
3.59 | 3.20 | 5.17 | 7.47 | 8.87 | 2.25 | 4.15 | 5.12 | — |
Net Debt/EBITDA |
0.21 | 0.34 | 1.08 | 1.68 | 1.85 | 0.28 | 0.91 | 1.20 | — |
Debt/Assets |
35.48% | 23.04% | 10.91% | 8.88% | 7.10% | 20.15% | 14.63% | 0.25% | 0.00% |
Debt/Equity |
0.76 | 0.40 | 0.15 | 0.12 | 0.09 | 26.87 | 0.22 | 0.00 | — |
Asset Turnover |
0.10 | 0.06 | 0.04 | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 | — |
Operating CF/Net income |
1.19 | 0.97 | 1.00 | 0.87 | 0.58 | 0.78 | 0.86 | 0.85 | — |
Capex/Depreciation |
1.43 | (0.13) | 0.08 | (1.06) | (0.61) | (5.06) | (1.52) | 0.00 | — |
Interest Coverage |
— | — | — | — | — | — | — | (120.51) | — |
| (79.75%) | (74.28%) | (48.69%) | (41.79%) | (135.83%) | 80.54% | 98.68% | 37.51% | — | |
| (42.69%) | (48.66%) | (35.71%) | (32.90%) | (55.66%) | (127.86%) | (94.65%) | (145.09%) | — | |
ROIC |
(119.22%) | (142.45%) | (170.15%) | (247.18%) | (67.63%) | 0.00% | (493.51%) | 0.00% | — |
Return on Tangible Assets |
(144.67%) | (165.68%) | (76.71%) | (56.44%) | (56.66%) | (334.04%) | (106.48%) | (90.63%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
370.80% | 747.32% | 781.39% | 1,276.37% | 6,004.37% | 17,470.56% | 12,093.95% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
179.27% | 240.01% | 286.06% | 400.19% | 1,459.76% | 3,920.35% | 2,410.23% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
36.15% | 96.32% | 117.10% | 167.15% | 674.60% | 614.72% | 236.28% | — | — |
Graham Net Nets |
0.00 | 0.41 | 1.34 | 2.28 | 0.81 | (0.30) | (0.30) | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,571.53 | 0.00 | — | — |
Earnings Yield |
(325.78%) | (310.28%) | (157.76%) | (172.26%) | (64.08%) | (89.47%) | (89.47%) | — | — |
Free Cash Flow Yield |
(380.87%) | (300.36%) | (158.98%) | (153.29%) | (36.52%) | (73.85%) | (73.85%) | — | — |
Revenue per Share |
4.12 | 4.03 | 4.17 | 3.07 | 0.76 | 2.20 | 2.16 | 0.00 | — |
Operating CF per Share |
(21.31) | (32.11) | (36.77) | (40.96) | (34.38) | (450.12) | (264.22) | (0.28) | — |
Capex per Share |
0.48 | 0.06 | (0.11) | (1.05) | (1.41) | (31.04) | (5.10) | 0.00 | — |
Free Cash Flow per Share |
(20.83) | (32.05) | (36.88) | (42.00) | (35.79) | (481.16) | (269.32) | (0.28) | — |
Cash per Share |
14.82 | 25.20 | 54.05 | 90.42 | 112.19 | 217.30 | 349.31 | 0.39 | — |
Shareholders Equity per Share |
14.17 | 29.96 | 59.63 | 91.82 | 150.68 | 3.32 | 317.54 | 0.35 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
14.17 | 29.96 | 59.63 | 91.82 | 150.68 | 3.32 | 317.54 | 0.35 | — |
Free Cash Flow |
(38.96) | (61.18) | (69.73) | (78.46) | (59.40) | (50.57) | (26.85) | (9.87) | — |
Working Capital |
21.83 | 34.96 | 85.25 | 149.63 | 167.83 | 14.10 | 27.24 | 11.35 | — |
Capital Expenditures |
0.89 | 0.11 | (0.21) | (1.95) | (2.34) | (3.26) | (0.51) | (0.29) | — |
Net Current Asset Value |
0.02 | 8.38 | 58.67 | 116.45 | 131.56 | (20.83) | 19.11 | 10.55 | — |
EV/EBIT |
0.00 | 0.06 | 0.54 | 1.08 | 0.02 | 0.00 | 0.00 | — | — |
Capex to Sales |
(0.12) | (0.01) | 0.03 | 0.34 | 1.86 | 14.12 | 2.36 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.50 | (0.27) | (0.53) | 0.29 | 0.62 | 0.16 | 0.24 | 0.21 | — |
Cash ROIC |
(52.41%) | (47.70%) | (30.01%) | (21.76%) | (12.96%) | (155.30%) | (36.50%) | (37.83%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 11.46 | 11.89 | 1.48 | 1.38 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,078.08 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | — |
Average Receivables |
— | — | — | 0.50 | 0.11 | 0.16 | 0.16 | — | — |
Average Payables |
1.48 | 2.25 | 3.29 | 3.58 | 2.59 | 1.85 | 1.49 | 1.49 | — |
Average Assets |
78.19 | 129.71 | 193.80 | 267.76 | 177.13 | 47.49 | 32.21 | 7.99 | — |
Average Common Equity |
41.85 | 84.97 | 142.12 | 210.81 | 72.59 | (75.40) | (30.89) | (30.89) | — |
Columns are period end dates